BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 23819399)

  • 1. Immunoexpression of the PTEN protein and matrix metalloproteinase-2 in endometrial cysts, endometrioid and clear cell ovarian cancer.
    Brucka A; Szyłło K
    Ginekol Pol; 2013 May; 84(5):344-51. PubMed ID: 23819399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary.
    Sato N; Tsunoda H; Nishida M; Morishita Y; Takimoto Y; Kubo T; Noguchi M
    Cancer Res; 2000 Dec; 60(24):7052-6. PubMed ID: 11156411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunohistochemical expression of PTEN antigen: a new tool for diagnosis of early endometrial neoplasia].
    Taranger-Charpin C; Carpentier S; Dales JP; Garcia S; Djemli A; Andrac L; Lavaut MN; Sferlazzo K; Boubli L
    Bull Acad Natl Med; 2004; 188(3):415-27; discussion 427-9. PubMed ID: 15584653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synchronous endometrial and ovarian carcinomas: predictors of risk and associations with survival and tumor expression profiles.
    Kelemen LE; Rambau PF; Koziak JM; Steed H; Köbel M
    Cancer Causes Control; 2017 May; 28(5):447-457. PubMed ID: 28194593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes.
    Alkushi A; Köbel M; Kalloger SE; Gilks CB
    Int J Gynecol Pathol; 2010 Jul; 29(4):343-50. PubMed ID: 20567148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.
    Huang HN; Lin MC; Tseng LH; Chiang YC; Lin LI; Lin YF; Huang HY; Kuo KT
    Histopathology; 2015 Mar; 66(4):517-28. PubMed ID: 25195947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pathogenic role of PTEN tumor suppressor gene in ovarian cancer associated to endometriosis].
    Castiblanco G A; Pires N Y; Wistuba O I; Riquelme S E; Andrade M L; Corvalán R A
    Rev Med Chil; 2006 Mar; 134(3):271-8. PubMed ID: 16676097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance and diagnostic value of PTEN and p53 expression in endometrial carcinoma. A retrospective clinicopathological and immunohistochemical study.
    Daniilidou K; Frangou-Plemenou M; Grammatikakis J; Grigoriou O; Vitoratos N; Kondi-Pafiti A
    J BUON; 2013; 18(1):195-201. PubMed ID: 23613406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression of beta-catenin, Glut-1, PTEN proteins in uterine endometrioid adenocarcinoma and its precursor lesions].
    Xiong Y; Xiong YY; Zhou YF
    Zhonghua Bing Li Xue Za Zhi; 2009 Sep; 38(9):594-9. PubMed ID: 20079187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix metalloproteinases 2 and 9, E-cadherin, and beta-catenin expression in endometriosis, low-grade endometrial carcinoma and non-neoplastic eutopic endometrium.
    Shaco-Levy R; Sharabi S; Benharroch D; Piura B; Sion-Vardy N
    Eur J Obstet Gynecol Reprod Biol; 2008 Aug; 139(2):226-32. PubMed ID: 18295959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. L1CAM expression associates with poor outcome in endometrioid, but not in clear cell ovarian carcinoma.
    Soovares P; Pasanen A; Bützow R; Lassus H
    Gynecol Oncol; 2017 Sep; 146(3):615-622. PubMed ID: 28625395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic significance of stage I ovarian clear cell and endometrioid carcinomas arising from endometriotic cysts: is it a myth?
    Ayhan A; Akilli H; Haberal N
    Arch Gynecol Obstet; 2019 Jan; 299(1):217-222. PubMed ID: 30315413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ARID1A, p53 and ß-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium.
    Heckl M; Schmoeckel E; Hertlein L; Rottmann M; Jeschke U; Mayr D
    PLoS One; 2018; 13(2):e0192881. PubMed ID: 29451900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases.
    Darvishian F; Hummer AJ; Thaler HT; Bhargava R; Linkov I; Asher M; Soslow RA
    Am J Surg Pathol; 2004 Dec; 28(12):1568-78. PubMed ID: 15577675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative immunohistochemical studies of bcl-2 and p53 proteins in benign and malignant ovarian endometriotic cysts.
    Nezhat F; Cohen C; Rahaman J; Gretz H; Cole P; Kalir T
    Cancer; 2002 Jun; 94(11):2935-40. PubMed ID: 12115382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus.
    Kimura F; Watanabe J; Hata H; Fujisawa T; Kamata Y; Nishimura Y; Jobo T; Kuramoto H
    J Cancer Res Clin Oncol; 2004 Mar; 130(3):161-8. PubMed ID: 14689303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoexpression and clinical significance of the PTEN and MLH1 proteins in endometrial carcinomas.
    Bąkiewicz A; Michalak J; Sporny S
    Pol J Pathol; 2010; 61(4):185-91. PubMed ID: 21290340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas.
    Catasús L; Bussaglia E; Rodrguez I; Gallardo A; Pons C; Irving JA; Prat J
    Hum Pathol; 2004 Nov; 35(11):1360-8. PubMed ID: 15668893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.
    Obata K; Morland SJ; Watson RH; Hitchcock A; Chenevix-Trench G; Thomas EJ; Campbell IG
    Cancer Res; 1998 May; 58(10):2095-7. PubMed ID: 9605750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma.
    Ayhan A; Mao TL; Seckin T; Wu CH; Guan B; Ogawa H; Futagami M; Mizukami H; Yokoyama Y; Kurman RJ; Shih IeM
    Int J Gynecol Cancer; 2012 Oct; 22(8):1310-5. PubMed ID: 22976498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.